Brightseed Launches BioMetaControl™, a Nature-Inspired GLP-1 Companion for Metabolic Health

Audio By Carbonatix

SAN FRANCISCO--(BUSINESS WIRE)--Sep 18, 2025--

Brightseed, the company unlocking the power of nature’s bioactives to elevate human health, today announced the commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health. This launch marks Brightseed’s expansion beyond digestive wellness into the growing field of blood glucose management and metabolic support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918348916/en/

Brightseed, the company unlocking the power of nature’s bioactives to elevate human health, today announced the commercial debut of BioMetaControl™, its first bioactive ingredient targeted for metabolic health that supports glucose control, sustained energy, and digestive relief.

A Breakthrough in Metabolic Health: NCT and NFT

Blood glucose regulation is central to overall metabolic health. HNF4-alpha is a 'master metabolic switch' that plays a pivotal role in blood glucose regulation. Brightseed's proprietary AI platform, Forager®, successfully identified bioactives, n-trans-Caffeoyl Tyramine ( NCT ) and n-trans-Feruloyl Tyramine ( NFT ), as potent HNF4-alpha agonists. By activating HNF4α, bioactives in BioMetaControl have been shown to address three key consumer and GLP-1 user needs supported in a forthcoming peer-reviewed human clinical study :

• Glucose Control – Support healthy all-day and post-meal blood sugar levels, reduces glucose variability, and improves fasting blood glucose.
• Sustained Energy – Help stabilize blood sugar to minimize spikes and crashes, supporting energy throughout the day (based on study subject testimonials).
• Digestive Relief – Bioactives NCT & NFT have been shown to reduce bloating and GI discomfort, common challenges for GLP-1 users, in a separate study*.

Bioactives NCT & NFT: Clinically Proven Benefits for Blood Glucose Control, Energy (subject testimonials), and Digestive Relief

In a recent randomized, double-blind, parallel-arm, clinical study (n=126), NCT and NFT administered as BioMetaControl demonstrated a statistically significant improvement in fasting blood glucose, fasting insulin, and post-meal glucose levels in prediabetic subjects. BioMetaControl was found to improve these parameters in just 30 days.

These improvements were not only found in outcomes that represent a snapshot in time, such as fasting blood glucose, fasting insulin levels, and post-meal blood glucose levels, but also in measures of continuous glucose monitoring over a period of 24 hours.

The study results have been submitted to a peer-reviewed journal and are expected to be published in Q4 2025. In a separate, peer-reviewed and published study*, NCT and NFT at the same dose presented with digestive relief benefits emerging in under three weeks.

At a low daily dose of 120mg, BioMetaControl offers a high-impact, sustained-release solution that is easy to formulate into capsules, tablets, soft gels, or functional beverages.

Brightseed’s Forager® AI: From Discovery to Scale

Following the recent launch of Bio Gut Core, Brightseed’s clinically proven gut health ingredient, BioMetaControl is the latest example of Brightseed’s end-to-end capabilities: discovery through Forager AI, clinical validation, and production at scale. This launch demonstrates Brightseed’s ability to deliver proprietary bioactives from nature to market-ready ingredients, setting a new standard for precision bioactives in human health.

“BioMetaControl is a pivotal milestone for Brightseed as we expand into metabolic health, building on our foundation in digestive wellness and further proving Forager’s discovery capabilities,” said Lee Chae, Co-Founder and CEO, Brightseed. “We are excited to provide brands with a clinically proven, nature-powered solution that supports blood glucose control and complements the use of GLP-1 therapies.”

For more information about BioMetaControl and partnership opportunities, please visit https://www.brightseedbio.com/bio-meta-control/.

*DOI: https://doi.org/10.31989/bchd.v8i6.1655

About Brightseed

Brightseed®, the bioactives leader unlocking nature with AI to elevate human health, is a World Economic Global Innovator. Brightseed’s proprietary AI, Forager®, accelerates bioactive discovery, biological validation, and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Brightseed produces clinically-proven bioactives for dietary supplements, food & beverage CPG, specialty nutrition, and medical foods to power proactive health worldwide. Learn more at brightseedbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250918348916/en/

CONTACT: Media Contact

Nicki Briggs, MS, RDN

Communications, Brightseed

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY OTHER RETAIL ALTERNATIVE MEDICINE TECHNOLOGY HEALTH VITAMINS/SUPPLEMENTS OTHER SCIENCE RETAIL ARTIFICIAL INTELLIGENCE FITNESS & NUTRITION SCIENCE

SOURCE: Brightseed

Copyright Business Wire 2025.

PUB: 09/18/2025 11:00 AM/DISC: 09/18/2025 10:59 AM

http://www.businesswire.com/news/home/20250918348916/en